Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: Optimization by different ways of sequence rearrangements (shuffling)

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Almajhdi, Fahad N ^a   Senger, Tilo ^b   Amer, Haitham M ^a,c   Gissmann, Lutz ^a,b   Öhlschläger, Peter ^d  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Cairo University   (Egypt)

^d AACHEN UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; WART VIRUS VACCINE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN E7; REPRESSOR PROTEIN; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CANCER PREVENTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DESIGN; EMBRYO; ENHANCER REGION; FEMALE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOPLASM; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROCESS OPTIMIZATION; TUMOR REGRESSION; TUMOR VOLUME; ALPHAPAPILLOMAVIRUS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ALPHAPAPILLOMAVIRUS; ANIMALS; ANTIBODIES, VIRAL; CELL LINE, TUMOR; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; REPRESSOR PROTEINS; VACCINES, DNA;

EID: 84912553206     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113461     Document Type: Article

References (47)

1. Patel D, Shepherd PS, Naylor JA, McCance DJ (1989) Reactivities of polyclonal and monoclonal antibodies raised to the major capsid protein of human papillomavirus type 16. J Gen Virol 70: 69-77.
2. McLean CS, Churcher MJ, Meinke J, Smith GL, Higgins G, et al. (1990) Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus. J Clin Pathol 43: 488-492.
3. Kjaer SK, Frederiksen K, Munk C, Iftner T (2010) Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 102: 1478-1488.
4. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, et al. (2012) Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 206: 1645-1651.
5. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, et al. (2011) Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377: 2085-2092.
6. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, et al. (2012) Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13: 89-99.
7. Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, et al. (2012) Human papillomavirus vaccine introduction - the first five years. Vaccine 30: F139-148.
8. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2010) Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 102: 325-339.
9. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, et al. (2011) HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29: 2011-2014.
10. Kanodia S, Da Silva DM, Kast WM (2008) Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 122: 247-259.
11. Nieto K, Gissmann L, Schadlich L (2010) Human papillomavirus-specific immune therapy: failure and hope. Antivir Ther 15: 951-957.
12. Daayana S, Elkord E, Winters U, Pawlita M, Roden R, et al. (2010) Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 102: 1129-1136.
13. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, et al. (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361: 1838-1847.
14. Ohlschlager P, Pes M, Osen W, Durst M, Schneider A, et al. (2006) An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 24: 2880-2893.
15. Osen W, Peiler T, Ohlschlager P, Caldeira S, Faath S, et al. (2001) A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 19: 4276-4286.
16. Ohlschlager P, Spies E, Alvarez G, Quetting M, Groettrup M (2011) The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer 128: 473-481.
17. Hanke T, McMichael AJ (2000) Design and construction of an experimental HIV-1 vaccine for a year- 2000 clinical trial in Kenya. Nat Med 6: 951-955.
18. Kozak M (1987) At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 196: 947-950.
19. Kammerer R, Stober D, Riedl P, Oehninger C, Schirmbeck R, et al. (2002) Noncovalent association with stress protein facilitates cross-priming of CD8+ T cells to tumor cell antigens by dendritic cells. J Immunol 168: 108-117.
20. Wildeman AG (1988) Regulation of SV40 early gene expression. Biochem Cell Biol 66: 567-577.
21. Schumacher TN, Heemels MT, Neefjes JJ, Kast WM, Melief CJ, et al. (1990) Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 62: 563-567.
22. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, et al. (1993) Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23: 2242-2249.
23. Buck CB, Pastrana DV, Lowy DR, Schiller JT (2004) Efficient intracellular assembly of papillomaviral vectors. J Virol 78: 751-757.
24. Dean DA, Dean BS, Muller S, Smith LC (1999) Sequence requirements for plasmid nuclear import. Exp Cell Res 253: 713-722.
25. Wilson GL, Dean BS, Wang G, Dean DA (1999) Nuclear import of plasmid DNA in digitoninpermeabilized cells requires both cytoplasmic factors and specific DNA sequences. J Biol Chem 274: 22025-22032.
26. Henken FE, Oosterhuis K, Ohlschlager P, Bosch L, Hooijberg E, et al. (2012) Preclinical safety evaluation of DNA vaccines encoding modified HPV16 E6 and E7. Vaccine 30: 4259-4266.
27. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
28. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, et al. (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802.
29. Bodily J, Laimins LA (2010) Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol 19: 33-39.
30. Hopfl R, Heim K, Christensen N, Zumbach K, Wieland U, et al. (2000) Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 356: 1985-1986.
31. Stern PL (2005) Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol 32: S72-81.
32. Jochmus I, Schafer K, Faath S, Muller M, Gissmann L (1999) Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res 30: 269-274.
33. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, et al. (2002) Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8: 3676-3685.
34. van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, et al. (1999) Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 35: 946-952.
35. Lin K, Roosinovich E, Ma B, Hung CF, Wu TC (2010) Therapeutic HPV DNA vaccines. Immunol Res 47: 86-112.
36. Shi W, Bu P, Liu J, Polack A, Fisher S, et al. (1999) Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J Virol 73: 7877-7881.
37. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, et al. (2000) Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 121: 216-225.
38. Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H, et al. (2002) Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 294: 47-59.
39. Cassetti MC, McElhiney SP, Shahabi V, Pullen JK, Le Poole IC, et al. (2004) Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 22: 520-527.
40. Polakova I, Pokorna D, Duskova M, Smahel M (2010) DNA vaccine against human papillomavirus type 16: modifications of the E6 oncogene. Vaccine 28: 1506-1513.
41. Oosterhuis K, Ohlschlager P, van den Berg JH, Toebes M, Gomez R, et al. (2011) Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. Int J Cancer 129: 397-406.
42. Schirmbeck R, Kwissa M, Fissolo N, Elkholy S, Riedl P, et al. (2002) Priming polyvalent immunity by DNA vaccines expressing chimeric antigens with a stress protein-capturing, viral J-domain. FASEB J 16: 1108-1110.
43. Li S, MacLaughlin FC, Fewell JG, Gondo M, Wang J, et al. (2001) Muscle-specific enhancement of gene expression by incorporation of SV40 enhancer in the expression plasmid. Gene Ther 8: 494-497.
44. Williams SG, Cranenburgh RM, Weiss AM, Wrighton CJ, Sherratt DJ, et al. (1998) Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res 26: 2120-2124.
45. Schoenberg DR, Maquat LE (2012) Regulation of cytoplasmic mRNA decay. Nat Rev Genet 13: 246-259.
46. Varshavsky A (1992) The N-end rule. Cell 69: 725-735.
47. Kisselev AF, Akopian TN, Castillo V, Goldberg AL (1999) Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell 4: 395-402.